23.49
Overview
News
Price History
Option Chain
Financials
Why PFE Down?
Discussions
Forecast
Stock Split
Dividend History
Pfizer Inc stock is traded at $23.49, with a volume of 51.27M.
It is up +0.86% in the last 24 hours and down -6.19% over the past month.
Pfizer is one of the world's largest pharmaceutical firms, with annual sales of roughly $60 billion. While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13, cancer drug Ibrance, and cardiovascular treatment Eliquis. Pfizer sells these products globally, with international sales representing 40% of total sales. Within international sales, emerging markets are a major contributor.
See More
Previous Close:
$23.29
Open:
$23.3
24h Volume:
51.27M
Relative Volume:
1.23
Market Cap:
$133.55B
Revenue:
$62.46B
Net Income/Loss:
$7.88B
P/E Ratio:
17.02
EPS:
1.38
Net Cash Flow:
$11.22B
1W Performance:
-5.24%
1M Performance:
-6.19%
6M Performance:
-11.43%
1Y Performance:
-23.36%
Pfizer Inc Stock (PFE) Company Profile
Name
Pfizer Inc
Sector
Industry
Phone
(212) 733-2323
Address
66 HUDSON BOULEVARD EAST, NEW YORK, NY
Compare PFE with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
PFE
Pfizer Inc
|
23.49 | 132.41B | 62.46B | 7.88B | 11.22B | 1.38 |
![]()
LLY
Lilly Eli Co
|
762.33 | 664.39B | 49.00B | 11.11B | -1.27B | 12.29 |
![]()
JNJ
Johnson Johnson
|
167.33 | 396.75B | 90.63B | 22.66B | 16.40B | 9.35 |
![]()
ABBV
Abbvie Inc
|
195.22 | 333.89B | 58.33B | 3.76B | 15.39B | 2.10 |
![]()
NVS
Novartis Ag Adr
|
115.30 | 220.18B | 55.19B | 13.65B | 16.81B | 6.86 |
![]()
MRK
Merck Co Inc
|
79.29 | 196.16B | 63.62B | 16.41B | 17.04B | 6.49 |
Pfizer Inc Stock (PFE) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Apr-22-25 | Initiated | Cantor Fitzgerald | Neutral |
Dec-10-24 | Resumed | BofA Securities | Neutral |
Nov-15-24 | Initiated | Wolfe Research | Underperform |
Oct-25-24 | Resumed | Citigroup | Neutral |
Oct-17-24 | Initiated | Bernstein | Mkt Perform |
Aug-07-24 | Upgrade | Daiwa Securities | Neutral → Outperform |
Mar-22-24 | Downgrade | Argus | Buy → Hold |
Feb-23-24 | Initiated | Guggenheim | Buy |
Jan-04-24 | Downgrade | TD Cowen | Outperform → Market Perform |
Oct-20-23 | Resumed | UBS | Neutral |
Oct-16-23 | Upgrade | Jefferies | Hold → Buy |
Jul-17-23 | Reiterated | JP Morgan | Neutral |
Jul-14-23 | Initiated | HSBC Securities | Buy |
Jun-29-23 | Downgrade | Credit Suisse | Outperform → Neutral |
May-11-23 | Downgrade | Daiwa Securities | Outperform → Neutral |
Mar-06-23 | Initiated | Jefferies | Hold |
Feb-07-23 | Upgrade | Daiwa Securities | Neutral → Outperform |
Jan-26-23 | Downgrade | UBS | Buy → Neutral |
Jan-17-23 | Downgrade | Wells Fargo | Overweight → Equal Weight |
Jan-04-23 | Downgrade | BofA Securities | Buy → Neutral |
Dec-13-22 | Upgrade | Goldman | Neutral → Buy |
Nov-18-22 | Initiated | Credit Suisse | Outperform |
May-23-22 | Initiated | SVB Leerink | Mkt Perform |
Apr-06-22 | Resumed | Morgan Stanley | Equal-Weight |
Jan-05-22 | Upgrade | BofA Securities | Neutral → Buy |
Jan-03-22 | Reiterated | Bernstein | Mkt Perform |
Dec-20-21 | Reiterated | Cowen | Outperform |
Dec-17-21 | Initiated | Goldman | Neutral |
Dec-13-21 | Upgrade | UBS | Neutral → Buy |
Dec-09-21 | Initiated | Wells Fargo | Overweight |
Nov-19-21 | Initiated | BMO Capital Markets | Outperform |
Jul-27-21 | Resumed | Truist | Buy |
May-06-21 | Downgrade | Mizuho | Buy → Neutral |
Apr-07-21 | Resumed | RBC Capital Mkts | Sector Perform |
Feb-04-21 | Upgrade | DZ Bank | Hold → Buy |
Dec-16-20 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
Nov-19-20 | Resumed | Goldman | Neutral |
Nov-10-20 | Resumed | Bernstein | Mkt Perform |
Oct-12-20 | Downgrade | Atlantic Equities | Overweight → Neutral |
Sep-29-20 | Initiated | Berenberg | Hold |
Jun-16-20 | Initiated | SVB Leerink | Mkt Perform |
Feb-27-20 | Initiated | Barclays | Equal Weight |
Feb-27-20 | Upgrade | Standpoint Research | Hold → Buy |
Feb-06-20 | Initiated | Mizuho | Buy |
Jan-07-20 | Initiated | RBC Capital Mkts | Outperform |
Oct-17-19 | Resumed | BofA/Merrill | Neutral |
Jul-30-19 | Downgrade | BofA/Merrill | Buy → Neutral |
Jul-30-19 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
Jun-04-19 | Resumed | Morgan Stanley | Overweight |
Feb-20-19 | Resumed | Citigroup | Neutral |
Jan-31-19 | Upgrade | Argus | Hold → Buy |
Jan-31-19 | Upgrade | Credit Suisse | Neutral → Outperform |
Jan-23-19 | Downgrade | UBS | Buy → Neutral |
Dec-11-18 | Downgrade | JP Morgan | Overweight → Neutral |
Nov-01-18 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
View All
Pfizer Inc Stock (PFE) Latest News
Pfizer's Q2 Earnings Loom: A Strategic Assessment for Investors - AInvest
Pfizer CEO expected to attend Trump fundraiser after drug price cut demands - Anadolu Ajansı
When You Look Back in a Few Years, You'll Wish You Had Bought This Unstoppable Artificial Intelligence (AI) Stock - The Motley Fool
Pfizer CEO expected at Trump fundraiser - breakingthenews.net
Pfizer CEO attending $25 million fundraiser at Trump's golf club after president demands drug price cuts, sources say - CBS News
Scooplet: The CEO of @Pfizer, Albert Bourla, is among those expected at the fundraiser President Trump is attending tonight, sources told @CBSNews. Trump yday sent letters to pharmaceutical companies, including Pfizer, demanding they lower U.S. drug pri - twitter.com
Pfizer’s Abrysvo Study: A Closer Look at Safety in Pregnant Women and Infants - TipRanks
Pfizer’s Ngenla Study: A Closer Look at Long-Term Safety for GHD Treatment - TipRanks
Pfizer’s TALZENNA Study: A New Hope for Prostate Cancer Treatment? - TipRanks
Pfizer’s Latest Clinical Study Update: Avelumab and Axitinib in Renal Cell Cancer - TipRanks
Pfizer, BioNTech lose UK appeal to overturn Moderna's COVID vaccine patent win - Reuters
Pfizer’s New Study on PF-07934040: A Potential Game-Changer in Cancer Treatment? - TipRanks
Pfizer’s New Study on Abrocitinib: A Potential Breakthrough for Pediatric Eczema - TipRanks
Pfizer’s Ongoing Safety Study of BNT162b2 in Korea: Key Insights for Investors - TipRanks
Pfizer’s Phase 3 Study: Evaluating Co-administration of RSV and Shingles Vaccines - TipRanks
Moderna Fights Off Pfizer Challenge To Surviving mRNA IP - Law360
Moderna Wins UK Patent Battle Against Pfizer and BioNTech - BioSpace
Buy, Sell or Hold Pfizer Stock? Key Tips Ahead of Q2 Earnings - Nasdaq
Pfizer/BioNTech lose appeal to reverse Moderna’s COVID vaccine patent win in U.K. - Seeking Alpha
How To Trade Pfizer Stock Ahead of Its Upcoming Earnings? - Trefis
Should You Buy Pfizer (PFE) Stock Before August 5? Here's What History Says - MSN
Pfizer losses appeal in Moderna patent case - breakingthenews.net
UK Court of Appeal Confirms Moderna’s EP'949 Patent is Valid and Infringed by Pfizer/BioNTech - The Daily Reflector
Moderna Secures Major Patent Victory: UK Court Rules Pfizer Infringed COVID-19 Vaccine Technology - Stock Titan
Pfizer (PFE) Dips More Than Broader Market: What You Should Know - Yahoo Finance
Trump Demands Pharma Companies Slash US Drug Prices in Letter - Bloomberg
Trump demands largest pharma companies slash US drug prices - Yahoo Finance
Purdue and Gleaners Food Bank to Open Pharmacy, Concerns Over Eli Lilly and Pfizer Relationship, IU Researchers get Top Awards, Ground Breaking for New Subsidized Housing - WFYI
Pfizer’s Promising Phase 2 Study on Advanced Breast Cancer Treatment - TipRanks
Pfizer’s Promising Phase 3 Study on NSCLC Treatment: A Market Game-Changer? - TipRanks
Pfizer’s New Hope: PF-08046031 Study in Advanced Melanoma and Solid Tumors - TipRanks
Pfizer’s MagnetisMM-32 Study: A New Hope for Multiple Myeloma Treatment - TipRanks
Pfizer’s Latest Study on HER2-positive Breast Cancer: A Real-World Perspective - TipRanks
Pfizer’s COVID-19 Vaccine Study: Key Insights and Market Impact - TipRanks
Pfizer and Astellas Advance Prostate Cancer Study with Promising Drug Combo - TipRanks
Pfizer’s Phase 3 Study on Elranatamab vs. Lenalidomide: A Potential Game-Changer in Multiple Myeloma Treatment - TipRanks
Pfizer and Genmab’s Tivdak Study: Assessing Ocular Safety in Cervical Cancer Treatment - TipRanks
Pfizer’s TALZENNA Study: A Potential Game-Changer in Breast Cancer Treatment - TipRanks
Pfizer’s Sisunatovir Study: A Promising Step in RSV Treatment - TipRanks
Pfizer’s Elranatamab Study: A Real-World Insight into Multiple Myeloma Treatment - TipRanks
Stay Ahead of the Game With Pfizer (PFE) Q2 Earnings: Wall Street's Insights on Key Metrics - Yahoo Finance
Pfizer: Lack Of Enthusiasm Shouldn't Surprise You - Seeking Alpha
Where Will Pfizer (PFE) Be in 5 Years? - AOL.com
Bank of America Securities Maintains a Hold on Pfizer (PFE) - Insider Monkey
Pfizer Shares Plunge 2.02% Amid Vaccine Advances and Cancer Deal, Ranked 118th in $860M Trading Volume - AInvest
Pfizer’s (PFE) Breakthrough Medicines Power its Dividend Stability - Insider Monkey
Pfizer and Astellas Pharma’s Promising mCRPC Study Update - TipRanks
Pfizer’s Gene Therapy Study for Duchenne Muscular Dystrophy: A Market Game-Changer? - TipRanks
Pfizer’s Phase 3 Study on Avelumab and Axitinib in Renal Cancer: A Market Game-Changer? - TipRanks
Pfizer’s New Study on Abrocitinib: A Potential Game-Changer for Pediatric Eczema - TipRanks
Pfizer’s Latest Clinical Study: A Potential Game-Changer in Cancer Treatment - TipRanks
Pfizer Inc Stock (PFE) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):